Neurophysiological biomarkers in [corticobasal syndrome (CBS)](/diseases/corticobasal-syndrome) provide valuable insights into cortical and subcortical dysfunction, offering potential for diagnosis, differential diagnosis, and disease progression monitoring. Unlike imaging biomarkers which provide structural information, neurophysiology captures the functional state of neural circuits, revealing synaptic dysfunction, membrane instability, and network dysconnectivity that precede visible atrophy["@boe2001"].
The characteristic neurophysiological profile of CBS includes severe motor cortex hyperexcitability (reflecting GABAergic dysfunction), asymmetric cortical slowing on EEG, prolonged central motor conduction, and progressive changes over time that mirror clinical deterioration. This profile is distinct from [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-palsy) (moderate hyperexcitability), [Parkinson's disease (PD)](/diseases/parkinsons-disease) (normal excitability), and [amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) (similar hyperexcitability but with upper motor neuron signs)[@gourdon2023].
One of the most consistent neurophysiological findings in [corticobasal syndrome (CBS)](/diseases/corticobasal-syndrome) is motor cortex hyperexcitability[@chen2024][@kim2024][@cantone2007]. This finding reflects dysfunction of [GABAergic](/mechanisms/gabaergic-dysfunction) inhibitory circuits and is useful in differential diagnosis against [Parkinson's disease (PD)](/diseases/parkinsons-disease) and [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-palsy).
The three classical TMS parameters in CBS show characteristic abnormalities:
| Parameter | Abbreviation | CBS Finding | Physiological Interpretation |
|-----------|-------------|-------------|----------------------------|
| Resting Motor Threshold | RMT | Reduced 10-15% | Increased membrane excitability of corticospinal neurons |
| Short-Interval Intracortical Inhibition | SICI | Severely reduced (often absent) | Loss of GABA-A receptor-mediated intracortical inhibition |
| Cortical Silent Period | CSP | Shortened 30-50% | Reduced GABA-B receptor-mediated recurrent inhibition |
The severity of SICI reduction in CBS exceeds that seen in [PSP](/diseases/progressive-supranuclear-palsy) and far exceeds that in [PD](/diseases/parkinsons-disease), making it one of the most discriminating TMS parameters[@tommasini2022][@priori2001].
SICI is tested by delivering a subthreshold conditioning stimulus (typically 70-80% of RMT) followed 1-5ms later by a suprathreshold test stimulus. In healthy individuals, the conditioning stimulus suppresses the motor evoked potential (MEP) amplitude by 50-80% via GABA-A receptor activation.
In CBS:
| Condition | SICI Level | Clinical Correlation |
|-----------|-----------|---------------------|
| CBS | Absent/severe reduction | Alien limb, apraxia, myoclonus |
| PSP | Moderate reduction | Axial rigidity, supranuclear gaze palsy |
| PD | Normal | Resting tremor, rigidity, bradykinesia |
| CBS-ALS overlap | Absent | Combined CBS + ALS features |
The CSP measures the interruption of voluntary EMG activity following a suprathreshold TMS pulse. In CBS, the CSP is shortened from the normal ~150ms to 60-90ms, reflecting reduced GABA-B receptor-mediated inhibition.
Correlation with clinical features:
While RMT reduction is less specific than SICI, it provides information about membrane-level excitability:
| TMS Parameter | [CBS](/diseases/corticobasal-syndrome) | [PSP](/diseases/progressive-supranuclear-palsy) | [PD](/diseases/parkinsons-disease) |
|-----------|-----------------------------------------|-----------------------------------------------|-----------------------------------|
| RMT | Reduced 10-15% | Reduced 5-8% | Normal |
| SICI | Severely reduced | Moderately reduced | Normal |
| CSP | Shortened 30-50% | Mildly shortened | Normal |
| CMCT | Prolonged (asymmetric) | Prolonged (symmetric) | Normal |
| MEP amplitude | Increased | Normal to slightly increased | Normal |
The asymmetric pattern of TMS abnormalities in CBS is particularly useful for distinguishing it from PSP, which typically shows more symmetric findings[@kim2024].
TBS delivers repetitive pulses at 5 Hz (theta frequency) in trains. Intermittent TBS (iTBS) facilitates motor cortex, while continuous TBS (cTBS) inhibits it.
CBS findings:
PAS combines peripheral nerve stimulation with TMS over the motor cortex at specific inter-stimulus intervals (typically 25ms, matching N20-P40 latency).
CBS findings:
TMS-EEG records cortical evoked responses following TMS pulses, providing information beyond motor outcomes[@benussi2023].
CBS-specific TMS-EEG findings:
Longitudinal TMS studies demonstrate progressive changes that mirror clinical deterioration[@wokacket2024]:
MEPs are recorded from target muscles following transcranial magnetic stimulation of the motor cortex. CMCT is calculated by subtracting the peripheral conduction time (from cervical spine to muscle) from the total MEP latency[@sasaki2023][@diLazzaro2012].
Normal values:
| Parameter | CBS Finding | Interpretation |
|-----------|-------------|----------------|
| Resting MEP amplitude | Increased | Reflects motor cortex hyperexcitability |
| MEP recruitment curve | Left-shifted | Lower stimulus intensity needed for maximal response |
| Stimulus-response curve slope | Steeper | Enhanced corticospinal excitability |
| Contralateral silent period | Shortened | GABA-B dysfunction |
The combination of increased MEP amplitude + shortened CSP is highly characteristic of CBS and differentiates it from PD (normal MEP amplitude, normal CSP) and PSP (intermediate findings)[@marinelli2017].
MEP abnormalities in CBS reflect involvement of the corticospinal pathway:
The asymmetric pattern of CMCT prolongation correlates with:
EEG in [CBS](/diseases/corticobasal-syndrome) shows characteristic patterns that reflect cortical dysfunction[@martinez2023]:
| EEG Finding | CBS Frequency | Normal | Clinical Significance |
|------------|--------------|--------|----------------------|
| Alpha rhythm | 8-10 Hz (slowed) | 10-12 Hz | Cortical dysfunction |
| Theta activity | Elevated (frontal) | Low | Executive dysfunction |
| Delta activity | Elevated (late disease) | Absent | Severe neurodegeneration |
| Asymmetry | Present | Absent | Lateralized cortical involvement |
Key characteristic: Asymmetric background slowing
Quantitative EEG provides objective measures of cortical activity[@Leodori2024]:
| qEEG Parameter | CBS Finding | PSP Finding | Clinical Correlation |
|----------------|--------------|-------------|---------------------|
| Alpha power (8-12 Hz) | Severely reduced | Moderately reduced | [Cognitive impairment](/mechanisms/cognitive-decline-neurodegeneration) |
| Theta power (4-8 Hz) | Elevated (frontal) | Diffuse elevation | Disease severity |
| Alpha/theta ratio | Markedly reduced | Reduced | Cognitive decline |
| Beta power (13-30 Hz) | Normal to reduced | Normal | Motor cortex involvement |
| Delta power (0.5-4 Hz) | Elevated (late disease) | Elevated (advanced) | Global dysfunction |
Advanced connectivity analysis reveals network-level dysfunction in CBS[@baratelli2021]:
Network analysis reveals:
The P300 is an ERP component generated when a subject detects an infrequent target stimulus among frequent non-target stimuli.
CBS findings:
SSEPs record cortical responses following peripheral nerve stimulation. In CBS, SSEPs reveal somatosensory pathway involvement[@marchettini2006]:
| SSEP Component | Finding in CBS | Interpretation |
|----------------|-----------------|----------------|
| N20 (primary somatosensory cortex) | Normal to slightly reduced | Variable cortical involvement |
| P37 (posterior parietal cortex) | Often prolonged/absent | Reflects cortical sensory loss |
| Central sensory conduction time | Prolonged | Subcortical white matter involvement |
Clinical correlation:
The combination of TMS + EEG findings creates a characteristic profile in CBS that discriminates it from other parkinsonisms:
| Feature | CBS | PSP | MSA-P | PD |
|---------|-----|-----|-------|----|
| SICI | Absent | Moderately reduced | Mildly reduced | Normal |
| CSP | Short | Mildly short | Normal | Normal |
| EEG asymmetry | Marked | Mild/symmetric | Symmetric | Absent |
| CMCT | Elevated (asymmetric) | Elevated (symmetric) | Variable | Normal |
| MEP amplitude | Increased | Normal | Normal | Normal |
| P300 latency | Markedly prolonged | Moderately prolonged | Normal to mildly prolonged | Normal |
Neurophysiological biomarkers serve as adjuncts to clinical diagnosis:
Serial neurophysiological assessments can track disease progression:
| Parameter | Change Over 12 Months | Clinical Correlation |
|-----------|----------------------|---------------------|
| SICI | Further reduction | Clinical worsening |
| CMCT | Prolongation | Motor disability increase |
| Alpha/theta ratio | Further decrease | Cognitive decline |
| EEG background | More slowing | Global deterioration |
These objective measures may serve as surrogate endpoints in clinical trials.
Neurophysiological biomarkers offer advantages for clinical trial endpoints:
Neurophysiological data integrates with other diagnostic modalities to improve classification:
Combining neurophysiology with imaging and fluid biomarkers:
The combination of asymmetric neurophysiological findings + asymmetric imaging + biomarker positivity provides high confidence for CBS vs. PSP differentiation.
Emerging studies use machine learning to combine neurophysiological features:
CBS overlaps clinically and pathologically with [ALS](/diseases/amyotrophic-lateral-sclerosis) and [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia). Neurophysiology reveals shared and distinct features:
| Feature | CBS | ALS |
|---------|-----|-----|
| SICI | Absent | Absent (similar hyperexcitability) |
| CMCT | Prolonged (asymmetric) | Prolonged (often symmetric) |
| Motor neuron loss | Limited | Extensive |
| Fasciculations | Rare | Common |
| EMG | Mild reinnervation changes | Active denervation |
Both CBS and ALS show motor cortex hyperexcitability, but:
| Feature | CBS | FTD |
|---------|-----|-----|
| EEG slowing | Prominent | Moderate |
| P300 | Markedly prolonged | Prolonged |
| Executive dysfunction | Present | Severe |
| Language deficits | Variable | Common (primary) |
| TMS | Hyperexcitability | Variable |
Neurophysiological biomarkers in [CBS](/diseases/corticobasal-syndrome) provide valuable insights into the underlying [neurodegeneration](/diseases/neurodegeneration). The characteristic pattern of motor cortex hyperexcitability (severe SICI reduction + shortened CSP) combined with asymmetric EEG slowing distinguishes CBS from [PSP](/diseases/progressive-supranuclear-palsy), [PD](/diseases/parkinsons-disease), and [ALS](/diseases/amyotrophic-lateral-sclerosis).
Key discriminators:
Integrating TMS, EEG, and MEP data with clinical features, imaging, and fluid biomarkers enables accurate diagnosis, disease staging, and monitoring of therapeutic interventions.